Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
15 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Symkevi“
Suchtreffer
Begriffe & Kennungen
Symkevi · 4.8 · Description of selected adverse reactions
Eintrag öffnenSymkevi · 4.8 · During the adult placebo-controlled phase 3 studies (up to 24 weeks), the incidence of maximum transaminase (A
Eintrag öffnenSymkevi · 4.8 · Other special populations
Eintrag öffnenSymkevi · 4.8 · Paediatric population
Eintrag öffnenSymkevi · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenSymkevi · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenSymkevi · 4.8 · Summary of the safety profile
Eintrag öffnenSymkevi · 4.8 · Table 4 reflects adverse reactions observed with Symkevi in combination with ivacaftor and with ivacaftor mono
Eintrag öffnenSymkevi · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenSymkevi · 4.8 · The most common adverse reactions experienced by patients aged 12 years and older who received Symkevi in comb
Eintrag öffnenSymkevi · 4.8 · The safety data from 1042 adults and 130 children aged 6 to less than 12 years old, treated with Symkevi in co
Eintrag öffnenSymkevi · 4.8 · The safety of Symkevi in combination with ivacaftor was evaluated in 124 patients between 6 to less than 12 ye
Eintrag öffnenSymkevi · 4.8 · The safety profile is generally consistent among children and adolescents, and is also consistent with adult p
Eintrag öffnenSymkevi · 4.8 · The safety profile of Symkevi in combination with ivacaftor, including respiratory events (e.g., chest discomf
Eintrag öffnenSymkevi · 4.8 · Transaminase elevations
Eintrag öffnen